Having demonstrated in vivo targeting of TCR-NYE to J82-NY-ESO157–165 cells and tumor prevention by ImmTAC-NYE in a xenograft model harboring both SK-Mel-37-NY-ESO157–165 cells and hu-CD45+CD3+ T-cell populations, we sought to evaluate anti-tumor efficacy of ImmTAC-NYE using optical imaging in pre-established tumors. This evidence concerns the gene PTPRC and neoplasm.